A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity

Clinical Nutrition

Volumn 34, Issue 5, 2015, Pages 845-858

  Beserra, Bruna T S ^a   Fernandes, Ricardo ^a   do Rosario, Vinicius A ^a   Mocellin, Michel C ^a   Kuntz, Marilyn G F ^a   Trindade, Erasmo B S M ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Meta analysis; Obesity; Overweight; Prebiotic; Synbiotic

Indexed keywords

FRUCTOSE OLIGOSACCHARIDE; GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREBIOTIC AGENT; SYNBIOTIC AGENT; TRIACYLGLYCEROL; CHOLESTEROL; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; AGE DISTRIBUTION; ARTICLE; BIFIDOBACTERIUM; BLOATING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DIET SUPPLEMENTATION; DYSLIPIDEMIA; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LACTOBACILLUS; LIPID ANALYSIS; LIPID BLOOD LEVEL; META ANALYSIS; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; STREPTOCOCCUS; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VALIDATION STUDY; BLOOD; DIET RESTRICTION; FACTUAL DATABASE; METABOLISM; OVERWEIGHT; REPRODUCIBILITY;

BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DATABASES, FACTUAL; FASTING; HUMANS; INSULIN; OBESITY; OVERWEIGHT; PREBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SYNBIOTICS; TRIGLYCERIDES;

EID: 84939178847     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2014.10.004     Document Type: Article

References (40)

1. Olshansky S.J., Passaro D.J., Hershow R.C., Layden J., Carnes B.A., Brody J., et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005, 352:1138-1145.
2. Organization WH Obesity: preventing and managing the global epidemic 2000, Technical report no 894, WHO, Geneva,.
3. Karastergiou K., Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol 2010, 318:69-78.
4. Fernandes R., Beserra B.T.S., Cunha R.S.G., Hillesheim E., Camargo C.deQ., Pequito D.C.T., et al. Relationship between acute phase proteins and serum fatty acid composition in morbidly obese patients. Dis Markers 2013, 105-112.
5. Association AD Standards of medical care in diabetes-2013. Diabetes Care 2013, 36:S11-S66.
6. Jensen M.D., Ryan D.H., Apovian C.M., Ard J.D., Comuzzie A.G., Donato K.A., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task force on practice guidelines and the obesity society. Circulation 2014, 129(25 Suppl. 2):S102-S138.
7. Delzenne N.M., Neyrinck A.M., Backhed F., Cani P.D. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 2011, 7:639-646.
8. Larsen N., Vogensen F.K., van den Berg F.W., Nielsen D.S., Andreasen A.S., Pedersen B.K., et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010, 5:e9085.
9. Turnbaugh P.J., Hamady M., Yatsunenko T., Cantarel B.L., Duncan A., Ley R.E., et al. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
10. Roberfroid M., Gibson G.R., Hoyles L., McCartney A.L., Rastall R., Rowland I., et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010, 104(Suppl. 2):S1-S63.
11. Guarner F., Khan A.G., Garisch J., Eliakim R., Gangl A., Thomson A., et al. World Gastroenterology Organisation global guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 2012, 46:468-481.
12. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151:W65-W94.
13. Thomas B.H., Ciliska D., Dobbins M., Micucci S. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evid Based Nurs 2004, 1:176-184.
14. Moher D., Hopewell S., Schulz K.F., Montori V., Gotzsche P.C., Devereaux P.J., et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340:c869.
15. Wu X., Ma C., Han L., Nawaz M., Gao F., Zhang X., et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 2010, 61:69-78.
16. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions 2008, John Wiley & Sons, Chichester.
17. White I.R., Thomas J. Standardized mean differences in individually-randomized and cluster-randomized trials, with applications to meta-analysis. Clin Trials 2005, 2:141-151.
18. Parvin Dehghan B.P.G., Asgharijafarabadi Mohammad Effects of high performance inulin supplementation on glycemic status and lipid profile in women with type 2 diabetes: a randomized, placebo-controlled clinical trial. Health Promot Perspect 2013, 3:9.
19. Pourghassem Gargari B., Dehghan P., Aliasgharzadeh A., Asghari Jafar-Abadi M. Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes. Diabetes Metab J 2013, 37:140-148.
20. Balcazar-Munoz B.R., Martinez-Abundis E., Gonzalez-Ortiz M. Effect of oral inulin administration on lipid profile and insulin sensitivity in subjects with obesity and dyslipidemia. Rev Med Chil 2003, 131:597-604.
21. Asemi Z., Khorrami-Rad A., Alizadeh S.A., Shakeri H., Esmaillzadeh A. Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clin Nutr 2014, 33:198-203.
22. de Luis D.A., de la Fuente B., Izaola O., Aller R., Gutiérrez S., Morillo M., et al. Double blind randomized clinical trial controlled by placebo with a FOS enriched cookie on society and cardiovascular risk factors in obese patients. Nutr Hosp 2013, 28:78-85.
23. Dewulf E.M., Cani P.D., Claus S.P., Fuentes S., Puylaert P.G., Neyrinck A.M., et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013, 62:1112-1121.
24. Eslamparast T., Poustchi H., Zamani F., Sharafkhah M., Sharafkhah R., Hekmatdoost A., et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 2014, 99:535-542.
25. Genta S., Cabrera W., Habib N., Pons J., Carillo I.M., Grau A., et al. Yacon syrup: beneficial effects on obesity and insulin resistance in humans. Clin Nutr 2009, 28:182-187.
26. Luo J., Van Yperselle M., Rizkalla S.W., Rossi F., Bornet F.R., Slama G., et al. Chronic consumption of short-chain fructooligosaccharides does not affect basal hepatic glucose production or insulin resistance in type 2 diabetics. J Nutr 2000, 130:1572-1577.
27. Malaguarnera M., Vacante M., Antic T., Giordano M., Chisari G., Acquaviva R., et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012, 57:545-553.
28. Moroti C., Souza Magri L.F., de Rezende Costa M., Cavallini D.C., Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis 2012, 11:29.
29. Parnell J.A., Reimer R.A. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 2009, 89:1751-1759.
30. Tovar A.R., Caamano Mdel C., Garcia-Padilla S., García O.P., Duarte M.A., Rosado J.L., et al. The inclusion of a partial meal replacement with or without inulin to a calorie restricted diet contributes to reach recommended intakes of micronutrients and decrease plasma triglycerides: a randomized clinical trial in obese Mexican women. Nutr J 2012, 11:44.
31. Vulevic J., Juric A., Tzortzis G., Gibson G.R. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr 2013, 143:324-331.
32. Huang Guo X.-M.L., Zhang Qiu-Xiang, Tian Feng-Wei, Zhang Hao, Zhang He-Ping, Chen Wei Effects of inulin on the plasma lipid profile of normolipidemic and hyperlipidemic subjects. Clin Lipidol 2012, 7:8.
33. Brighenti F. Dietary fructans and serum triacylglycerols: a meta-analysis of randomized controlled trials. J Nutr 2007, 137:2552S-2556S.
34. Kellow N.J., Coughlan M.T., Reid C.M. Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. Br J Nutr 2013, 1-15.
35. Ng D.S. Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets. Can J Diabetes 2013, 37:319-326.
36. Creely S.J., McTernan P.G., Kusminski C.M., Fisher F.M., da Silva N.F., Khanolkar M., et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292:E740-E747.
37. Bonsu N.K., Johnson C.S., McLeod K.M. Can dietary fructans lower serum glucose?. J Diabetes 2011, 3:58-66.
38. Vespasiani-Gentilucci U., Carotti S., Perrone G., Mazzarelli C., Galati G., Onetti-Muda A., et al. Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD. Liver Int 2014, http://onlinelibrary.wiley.com/doi/10.1111/liv.12531/abstract.
39. Hardy H., Harris J., Lyon E., Beal J., Foey A.D. Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients 2013, 5:1869-1912.
40. Fedewa A., Rao S.S. Dietary fructose intolerance, fructan intolerance and FODMAPs. Curr Gastroenterol Rep 2014, 16:370.